July 8th 2021
The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection fraction.
February 3rd 2021
Pharmacists can help patients through education, therapy, and lifestyle modifications.
January 28th 2021
The latest Heart Disease and Stroke Statistical Update highlighted pandemic-related trends that may impact cardiovascular disease mortality for years.
January 22nd 2021
Investigators compared outcomes among patients with COVID-19 and hypertension through modifying blood pressure medication use.
December 17th 2020
An FDA panel voted to recommend the expanded use of sacubitril/valsartan (Entresto; Novartis).
Cardiovascular Risk Management Unmet Needs
A key opinion leader discusses the most significant unmet needs in the evolving spectrum of cardiovascular risk management.
REDUCE-IT Trial Data Updates: Key Takeaways
A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.
The Potential CV Impact of Triglyceride Level Reduction
An expert physician discusses the role of agents that reduce triglyceride levels and the potential on cardiovascular risk.
CV Risk Stratification Decision Factors
A discussion on which factors to consider when assessing the need for management/reduction of cardiovascular risk.
CV Health: Risk Prevention, Challenges, Education
A key opinion leader discusses effective risk prevention measures and challenges to reducing adverse events. He also considers effective educational resources for self-care.
New Approaches in Targeting Triglycerides for the Reduction of Cardiovascular Risks
This article reviews the evolving therapeutic landscape for lowering LDL-C and cardiovascular risk, with an emphasis on the role of omega-3 fatty acids.
2 Clarke Drive Cranbury, NJ 08512